Taylor Hennrick, PA
Physician Assistant · Adrian, MINPI 1982072435
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $381,573 of the $429,759 with a category attached, or 88.8%. AbbVie accounts for 78.4% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2023 at $151,115 and has fallen 55.9% since, to $66,651 in 2025. Among physician assistant clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,048 payments — averaging $410.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$337K
- Supernus Pharmaceuticals, Inc.$46K
- Vanda Pharmaceuticals Inc.$16K
- Otsuka America Pharmaceutical, Inc.$15K
- Axsome Therapeutics, Inc.$7K
- E.r. Squibb & Sons, L.L.C.$6K
- plus $3K from 19 others
What the payments were for
- Consulting fees$9,1602%
- Speaking & faculty fees$381,57389%
- Travel & lodging$23,4885%
- Food & beverage$15,4414%
- Education$960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 646 | $337,004 |
| Supernus Pharmaceuticals, Inc. | 98 | $46,379 |
| Vanda Pharmaceuticals Inc. | 27 | $15,524 |
| Otsuka America Pharmaceutical, Inc. | 87 | $14,787 |
| Axsome Therapeutics, Inc. | 20 | $6,867 |
| E.r. Squibb & Sons, L.L.C. | 22 | $5,816 |
| Neurocrine Biosciences, Inc. | 16 | $792 |
| Lundbeck LLC | 30 | $563 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $453 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $367 |
| Alkermes, Inc. | 15 | $361 |
| Teva Pharmaceuticals USA, Inc. | 6 | $216 |
| Johnson & Johnson | 4 | $153 |
| Sunovion Pharmaceuticals Inc. | 8 | $122 |
| Corium, LLC | 5 | $71 |
| Indivior Inc. | 4 | $67 |
| Tris Pharma Inc | 3 | $47 |
| Bausch Health US, LLC | 3 | $39 |
| Avanir Pharmaceuticals, Inc. | 1 | $25 |
| Tempus AI, Inc | 1 | $24 |
| Ironshore Pharmaceuticals Inc. | 1 | $21 |
| Sage Therapeutics, LLC | 1 | $20 |
| Eisai Inc. | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$429,759 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 47 | $70,341 |
| RexultiBrexpiprazole | 36 | $56,456 |
| Aripiprazole | 89 | $12,800 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,243 |
| Duloxetine Hcl | 132 | $3,313 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 105 | $2,321 |
| Alprazolam | 275 | $1,913 |
| Paroxetine ErParoxetine Hcl | 11 | $1,830 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 40 | $1,642 |
| Bupropion XlBupropion Hcl | 115 | $1,611 |
| Lamotrigine | 100 | $1,580 |
| Vilazodone Hcl | 13 | $1,355 |
| Quetiapine Fumarate | 97 | $1,352 |
| Trazodone Hcl | 117 | $1,296 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 29 | $1,254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $337,004 | $70,34147 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $14,787 | $56,45636 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $367 | $5,24311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.
Other physician assistant in Adrian
- Salah MansourAdrian$18K
- Sarang PatelRoyal Oak$660K
- Beth SweneyAda$617K
- Zainab JishiCanton$596K
- Erin van DykeGrand Rapids$346K
- Ashley AldridgeAnn Arbor$298K
- Derek SusallaRochester Hills$242K
- Gabrielle DamoreRoyal Oak$200K
- Melissa MickelsonKalamazoo$168K
- Patrick CooneyNew Baltimore$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.